Drug pricing is expected to be a hot topic in 2023—here’s what you need to know about the outlook and the importance of messaging. Plus, a new strain of a deadly pig disease highlights the importance of advancing animal biotech like gene editing. (618 words, 3 minutes,…
The only newsletter at the intersection of biotech, politics, and policy
January 30, 2023
Drug pricing is expected to be a hot topic in 2023—here’s what you need to know about the outlook and the importance of messaging. Plus, a new strain of a deadly pig disease highlights the importance of advancing animal biotech like gene editing. (618 words, 3 minutes, 5 seconds)
What you need to know about drug pricing in 2023
With the 118th Congress underway in earnest this week as committees begin work on key issues, there’s never been a more important time to discuss the harm price controls will do to R&D and patients.
Educating policymakers will be key: “We need to communicate what is important about our industry, and we need to make sure that legislators appreciate what it is that biotech brings, not only to the patients but to the communities that legislators serve,” said BIO’s Interim CEO Rachel King.
What’s next: While the outlook for drug price controls—and what they mean for patients—is troubling, there could be bipartisan opportunities to address some of the real drivers of rising out-of-pocket costs, specifically pharmacy benefit managers (PBMs) and 340B. Watch this space.
The Washington Post (Opinion): PEPFAR has made so much progress against AIDS. We can’t let up now. “U.S. policymakers can build on PEPFAR’s remarkable progress and save millions more lives by continuing their bipartisan support for global health programs, including congressional reauthorization of PEPFAR by September of this year,” writes Bill Gates.
New strain of deadly pig disease highlights need for animal biotech
A new variant of Porcine Reproductive and Respiratory Syndrome (PRRS) has spread to six U.S. states, reports Pig Progress—highlighting the importance of advancing animal biotech.
PRRS “is endemic to most swine-producing countries,”said a study published last year, but this particular strain is proving to evolve rapidly and be difficult to eliminate.
BIO’s Interim CEO Rachel King appeared on The BioCentury Show, where she said the organization’s top priorities in 2023 include guiding implementation of the Inflation Reduction Act (IRA), FDA’s accelerated approval pathway, capital formation, and diversity, equity, and inclusion, which she calls “the pathway to excellence.”
Kicking off what’s expected to be a busy year for the industry in Washington, D.C., King discusses public perceptions of the biotech industry, the need to find and nurture political champions, and the pressing concerns of BIO’s members.